Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840104 | 0.94 | HPGDS (0.58) | NPC1RAB9AHPGDSCYP2E1CYP3A4 | |
| SCHEMBL5761329 | 0.93 | CYP11B1 (0.54) | NPC1RAB9AHPGDSCDK5CDK5R1 | |
| SCHEMBL5757600 | 0.87 | NPC1 (0.61) | NPC1RAB9ACDK5CDK5R1MEN1 | |
| SCHEMBL5757721 | 0.87 | CLK1 (0.50) | NPC1RAB9ACDK5CDK5R1MEN1 | |
| SCHEMBL1346083 | 0.85 | HPGDS (0.77) | NPC1RAB9AHPGDSCYP2E1CYP3A4 | |
| SCHEMBL28702001 | 0.84 | NPC1 (0.64) | NPC1RAB9AHPGDSCYP2E1CYP3A4 | |
| SCHEMBL28714930 | 0.82 | HPGDS (0.64) | NPC1RAB9AHPGDSCYP2E1CYP3A4 | |
| SCHEMBL23123623 | 0.81 | CYP2E1 (0.49) | NPC1RAB9AHPGDSCYP2E1CYP3A4 | |
| SCHEMBL10991076 | 0.81 | HPGDS (0.62) | NPC1RAB9AHPGDSCYP2E1CYP3A4 | |
| SCHEMBL19311955 | 0.79 | MEN1 (0.57) | NPC1RAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| US-6559172-B1 | Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics | SMITHKLINE BEECHAM CORPORATION | 2003-05-06 | — | — | US | claimed |
| JP-2003500357-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1194144-A4 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| EP-1194144-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000071120-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-30 | — | — | WO | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
| US-6673941-B2 | Disubstituted imidazoles useful in the treatment of bacterial infections | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-01-06 | — | — | US | disclosed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-6559172-B1 | Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics | SMITHKLINE BEECHAM CORPORATION | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | NPC1 103/4885RAB9A 140/4885HPGDS 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.